The IND was withdrawn

This protocol (NLG0705) provides a mechanism for the 15-year follow-up period that the FDA requires for all participants in gene transfer protocols and assures that adequate follow-up can be maintained for subjects who have received at least one dose of algenpantucel-L.

Inclusion Criteria:

• Receipt of at least one dose of algenpantucel-L within the past 15 years
• Signed consent

Research subjects who have received at least one dose of algenpantucel-L immunotherapy in clinical trials.